-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
"Constructing China's Pharmaceutical Innovation Ecosystem-Part Two of the Report Series: Promoting Basic Research and Activating the Source of Innovation" (hereinafter referred to as the "Basic Research" Sub-Report") was "launched" on the 11th
.
Accordingly, in the past five years, China's biomedical basic research has been on the fast track, achieving continuous improvement in key areas such as funding, innovation entities, talent strategies, and institutional environment
.
.
Accordingly, in the past five years, China's biomedical basic research has been on the fast track, achieving continuous improvement in key areas such as funding, innovation entities, talent strategies, and institutional environment
.
Song Ruilin, executive chairman of the China Pharmaceutical Innovation Promotion Association (PhIRDA or China Pharmaceutical Promotion Association), said: “In the future, China’s basic research will move toward leading innovation and improve originality.
It must focus on basic research and transformational capacity building; the state will continue to strengthen basic research planning and Support, focusing on overcoming the key technologies of "stuck necks" in important areas and breaking through industrial bottlenecks is the key to promoting the high-quality development of the industry
.
"
It must focus on basic research and transformational capacity building; the state will continue to strengthen basic research planning and Support, focusing on overcoming the key technologies of "stuck necks" in important areas and breaking through industrial bottlenecks is the key to promoting the high-quality development of the industry
.
"
In early 2021, the China Pharmaceutical Innovation Promotion Association (PhIRDA or China Pharmaceutical Promotion Association) and the China Association of Foreign Investment Enterprises Pharmaceutical Research and Development Industry Committee (RDPAC) jointly led the launch of the "Building China's Pharmaceutical Innovation Ecosystem" series of reports, aiming to start from the top Starting from the design, we look for the weak links and challenges in the entire industry chain at the emergence stage, and put forward constructive opinions from multiple dimensions to promote the high-quality development of China's pharmaceutical innovation, and build an internationally oriented ecological environment suitable for the sustainable development of China's biomedical innovation
.
"Innovative industry competitiveness", "innovative medicines accessible" and "innovative pharmaceutical industry sustainable" are the three main lines
.
.
"Innovative industry competitiveness", "innovative medicines accessible" and "innovative pharmaceutical industry sustainable" are the three main lines
.
The "Basic Research" Sub-Report provides an in-depth analysis of the current status and challenges of China's biomedical basic research and translational research, and puts forward prospects and policy recommendations for China's development in this field in the next five years
.
Song Ruilin, executive chairman of the China Pharmaceutical Promotion Association, hopes that this report can bring new ideas, improve society’s awareness of creating a good ecological environment for basic research and scientific research, provide a full range of institutional guarantees for basic research, and encourage innovative entities to participate in the source Innovation
.
.
Song Ruilin, executive chairman of the China Pharmaceutical Promotion Association, hopes that this report can bring new ideas, improve society’s awareness of creating a good ecological environment for basic research and scientific research, provide a full range of institutional guarantees for basic research, and encourage innovative entities to participate in the source Innovation
.
According to the "Basic Research" Sub-Report, under the guidance of the national innovation-driven development strategy, China's biomedical basic research has been on the fast lane in the past five years, with investment in funding, innovation entities, talent strategies, institutional environment, etc.
Continued improvement in key areas has laid a solid foundation for the substantial progress of basic research in biomedicine
.
The "Basic Research" sub-report pointed out that at present, China's pharmaceutical innovation technology system has been initially established; domestic research institutions have continued to rise in international rankings; the number of top basic scientific research publications led or co-led by Chinese research teams has continued to increase
.
Continued improvement in key areas has laid a solid foundation for the substantial progress of basic research in biomedicine
.
The "Basic Research" sub-report pointed out that at present, China's pharmaceutical innovation technology system has been initially established; domestic research institutions have continued to rise in international rankings; the number of top basic scientific research publications led or co-led by Chinese research teams has continued to increase
.
The report also pointed out that, compared with the international level, the overall level of pharmaceutical innovation still lags behind the world's leading level, and is still in a state of "following" and "running in parallel"
.
Prominent problems and "bottleneck" include: unreasonable R&D investment distribution stage, high-quality frontier research needs to be improved, difficulty in patent conversion and output, and serious lack of professional institutions and talents
.
The report believes that the investment in basic research needs to be strengthened; the obvious problems of original innovation also include insufficient patent conversion output
.
Leading talents and teams among Chinese biomedical researchers are still scarce
.
At the same time, the talent evaluation system of medical institutions is relatively single and one-sided, the transformation research of medical institutions is insufficient, and there is a lack of compound talents with medical background and comprehensive ability of industrial experience
.
.
Prominent problems and "bottleneck" include: unreasonable R&D investment distribution stage, high-quality frontier research needs to be improved, difficulty in patent conversion and output, and serious lack of professional institutions and talents
.
The report believes that the investment in basic research needs to be strengthened; the obvious problems of original innovation also include insufficient patent conversion output
.
Leading talents and teams among Chinese biomedical researchers are still scarce
.
At the same time, the talent evaluation system of medical institutions is relatively single and one-sided, the transformation research of medical institutions is insufficient, and there is a lack of compound talents with medical background and comprehensive ability of industrial experience
.
How to face multiple challenges? Conway, CEO of RDPAC, believes that the basic research of China's pharmaceutical innovation also needs to break through pioneer scientific discoveries and disruptive technological inventions, and build a system and ability to transform basic research into industry
.
"Only by mastering basic innovation capabilities can China's pharmaceutical innovation reach a new level, and then make a source contribution to global pharmaceutical innovation
.
" The "Basic Research" sub-report believes that the talent system should be the center and from a strategic direction.
, Fund input, activation of innovation subjects from multiple perspectives, and continue to promote basic research to play the role of the source of medical innovation
.
Relevant departments should clarify basic research and its strategic value in the transformation of the pharmaceutical industry from the top-level plan, and lead the research direction.
It should focus on 11 directions including gene editing technology, stem cell and regenerative medicine, and antibody drug industry
.
.
"Only by mastering basic innovation capabilities can China's pharmaceutical innovation reach a new level, and then make a source contribution to global pharmaceutical innovation
.
" The "Basic Research" sub-report believes that the talent system should be the center and from a strategic direction.
, Fund input, activation of innovation subjects from multiple perspectives, and continue to promote basic research to play the role of the source of medical innovation
.
Relevant departments should clarify basic research and its strategic value in the transformation of the pharmaceutical industry from the top-level plan, and lead the research direction.
It should focus on 11 directions including gene editing technology, stem cell and regenerative medicine, and antibody drug industry
.
In terms of the evaluation of scientific research talents, we should guide the pursuit of original innovation, encourage the transformation of basic research results, try to establish a new system of interdisciplinary and cross-integrated research and development institutions, and promote medical research linkages and industry-university collaboration
.
.
During the interview, Conway said that RDPAC and its member companies look forward to sharing international cases and experiences, promoting international cooperation, and comprehensively assisting the gradual formation and improvement of China's pharmaceutical innovation industry chain and enhancing innovation capabilities
.
( China News Network )
.
( China News Network )
"Constructing China's Pharmaceutical Innovation Ecosystem-Part Two of the Report Series: Promoting Basic Research and Activating the Source of Innovation" (hereinafter referred to as the "Basic Research" Sub-Report") was "launched" on the 11th
.
Accordingly, in the past five years, China's biomedical basic research has been on the fast track, achieving continuous improvement in key areas such as funding, innovation entities, talent strategies, and institutional environment
.
.
Accordingly, in the past five years, China's biomedical basic research has been on the fast track, achieving continuous improvement in key areas such as funding, innovation entities, talent strategies, and institutional environment
.
Song Ruilin, executive chairman of the China Pharmaceutical Innovation Promotion Association (PhIRDA or China Pharmaceutical Promotion Association), said: “In the future, China’s basic research will move toward leading innovation and improve originality.
It must focus on basic research and transformational capacity building; the state will continue to strengthen basic research planning and Support, focusing on overcoming the key technologies of "stuck necks" in important areas and breaking through industrial bottlenecks is the key to promoting the high-quality development of the industry
.
"
It must focus on basic research and transformational capacity building; the state will continue to strengthen basic research planning and Support, focusing on overcoming the key technologies of "stuck necks" in important areas and breaking through industrial bottlenecks is the key to promoting the high-quality development of the industry
.
"
In early 2021, the China Pharmaceutical Innovation Promotion Association (PhIRDA or China Pharmaceutical Promotion Association) and the China Association of Foreign Investment Enterprises Pharmaceutical Research and Development Industry Committee (RDPAC) jointly led the launch of the "Building China's Pharmaceutical Innovation Ecosystem" series of reports, aiming to start from the top Starting from the design, we look for the weak links and challenges in the entire industry chain at the emergence stage, and put forward constructive opinions from multiple dimensions to promote the high-quality development of China's pharmaceutical innovation, and build an internationally oriented ecological environment suitable for the sustainable development of China's biomedical innovation
.
"Innovative industry competitiveness", "innovative medicines accessible" and "innovative pharmaceutical industry sustainable" are the three main lines
.
.
"Innovative industry competitiveness", "innovative medicines accessible" and "innovative pharmaceutical industry sustainable" are the three main lines
.
The "Basic Research" Sub-Report provides an in-depth analysis of the current status and challenges of China's biomedical basic research and translational research, and puts forward prospects and policy recommendations for China's development in this field in the next five years
.
Song Ruilin, executive chairman of the China Pharmaceutical Promotion Association, hopes that this report can bring new ideas, improve society’s awareness of creating a good ecological environment for basic research and scientific research, provide a full range of institutional guarantees for basic research, and encourage innovative entities to participate in the source Innovation
.
.
Song Ruilin, executive chairman of the China Pharmaceutical Promotion Association, hopes that this report can bring new ideas, improve society’s awareness of creating a good ecological environment for basic research and scientific research, provide a full range of institutional guarantees for basic research, and encourage innovative entities to participate in the source Innovation
.
According to the "Basic Research" Sub-Report, under the guidance of the national innovation-driven development strategy, China's biomedical basic research has been on the fast lane in the past five years, with investment in funding, innovation entities, talent strategies, institutional environment, etc.
Continued improvement in key areas has laid a solid foundation for the substantial progress of basic research in biomedicine
.
The "Basic Research" sub-report pointed out that at present, China's pharmaceutical innovation technology system has been initially established; domestic research institutions have continued to rise in international rankings; the number of top basic scientific research publications led or co-led by Chinese research teams has continued to increase
.
Continued improvement in key areas has laid a solid foundation for the substantial progress of basic research in biomedicine
.
The "Basic Research" sub-report pointed out that at present, China's pharmaceutical innovation technology system has been initially established; domestic research institutions have continued to rise in international rankings; the number of top basic scientific research publications led or co-led by Chinese research teams has continued to increase
.
The report also pointed out that, compared with the international level, the overall level of pharmaceutical innovation still lags behind the world's leading level, and is still in a state of "following" and "running in parallel"
.
Prominent problems and "bottleneck" include: unreasonable R&D investment distribution stage, high-quality frontier research needs to be improved, difficulty in patent conversion and output, and serious lack of professional institutions and talents
.
The report believes that the investment in basic research needs to be strengthened; the obvious problems of original innovation also include insufficient patent conversion output
.
Leading talents and teams among Chinese biomedical researchers are still scarce
.
At the same time, the talent evaluation system of medical institutions is relatively single and one-sided, the transformation research of medical institutions is insufficient, and there is a lack of compound talents with medical background and comprehensive ability of industrial experience
.
.
Prominent problems and "bottleneck" include: unreasonable R&D investment distribution stage, high-quality frontier research needs to be improved, difficulty in patent conversion and output, and serious lack of professional institutions and talents
.
The report believes that the investment in basic research needs to be strengthened; the obvious problems of original innovation also include insufficient patent conversion output
.
Leading talents and teams among Chinese biomedical researchers are still scarce
.
At the same time, the talent evaluation system of medical institutions is relatively single and one-sided, the transformation research of medical institutions is insufficient, and there is a lack of compound talents with medical background and comprehensive ability of industrial experience
.
How to face multiple challenges? Conway, CEO of RDPAC, believes that the basic research of China's pharmaceutical innovation also needs to break through pioneer scientific discoveries and disruptive technological inventions, and build a system and ability to transform basic research into industry
.
"Only by mastering basic innovation capabilities can China's pharmaceutical innovation reach a new level, and then make a source contribution to global pharmaceutical innovation
.
" The "Basic Research" sub-report believes that the talent system should be the center and from a strategic direction.
, Fund input, activation of innovation subjects from multiple perspectives, and continue to promote basic research to play the role of the source of medical innovation
.
Relevant departments should clarify basic research and its strategic value in the transformation of the pharmaceutical industry from the top-level plan, and lead the research direction.
It should focus on 11 directions including gene editing technology, stem cell and regenerative medicine, and antibody drug industry
.
.
"Only by mastering basic innovation capabilities can China's pharmaceutical innovation reach a new level, and then make a source contribution to global pharmaceutical innovation
.
" The "Basic Research" sub-report believes that the talent system should be the center and from a strategic direction.
, Fund input, activation of innovation subjects from multiple perspectives, and continue to promote basic research to play the role of the source of medical innovation
.
Relevant departments should clarify basic research and its strategic value in the transformation of the pharmaceutical industry from the top-level plan, and lead the research direction.
It should focus on 11 directions including gene editing technology, stem cell and regenerative medicine, and antibody drug industry
.
In terms of the evaluation of scientific research talents, we should guide the pursuit of original innovation, encourage the transformation of basic research results, try to establish a new system of interdisciplinary and cross-integrated research and development institutions, and promote medical research linkages and industry-university collaboration
.
.
During the interview, Conway said that RDPAC and its member companies look forward to sharing international cases and experiences, promoting international cooperation, and comprehensively assisting the gradual formation and improvement of China's pharmaceutical innovation industry chain and enhancing innovation capabilities
.
( China News Network )
.
( China News Network )
